Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Overview
The primary objective of this study is to gather stool samples from subjects with inflammatory bowel disease (IBD) to be added to a test set of stool samples that will be utilized to help select molecular markers and determine the optimal sensitivity and specificity values for the Exact IBD-ACRN surveillance test for colorectal cancer (CRC).
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: November 2015
Interventions
- Device: Stool Collection Kit
- Stool Collection Kit.
Arms, Groups and Cohorts
- IBD
- Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings.
Clinical Trial Outcome Measures
Primary Measures
- Sensitivity and Specificity of the Exact CRC diagnostic screening test.
- Time Frame: 15 months
- The primary endpoint is point estimates of the sensitivity of the diagnostic test for detection of colorectal cancer in IBD patients.
Participating in This Clinical Trial
Inclusion Criteria
- Male or Female 18 – 84 years of age, inclusive, who have been diagnosed with IBD. – Willing to provide a stool sample ≤120 but ≥7 days after a surveillance colonoscopy, which was negative for cancer/dysplasia. – Written informed consent document signed and dated by the subject. Exclusion Criteria:
- Any condition that in the opinion of the investigator should preclude participation in the study. – A history of aerodigestive tract cancer. – Prior colorectal resection, except ileocolic resection in Crohn's disease patients. – IBD limited only to the rectum. – Subject has participated in any clinical study within the previous 30 days wherein an investigational compound or device was, or may have been, introduced into the subject.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 84 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Exact Sciences Corporation
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Graham Lidgard, PhD, Study Chair, Exact Sciences
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.